Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $27.04, giving the company a market capitalization of 153.76B. It carries a P/E multiple of 20.22 and pays a dividend yield of 6.3%.
As of 2026-03-20, Pfizer(PFE) stock has fluctuated between $26.90 and $27.55. The current price stands at $27.04, placing the stock +0.5% above today's low and -1.8% off the high.
Pfizer(PFE) shares are trading with a volume of 18.2M, against a daily average of 43.62M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
PFE News
Key Points Innovative drugmakers tend to perform well over the long run. These three drug stocks can launch new products while maintaining or improving their...
Key Points The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk....
In recent days, Pfizer reported positive topline data from multiple late-stage trials, including Phase 3 TALAPRO-3 in HRR gene‑mutated metastatic castration‑sen...
Analyst ratings
55%
of 29 ratingsMore PFE News
Pfizer Talzenna Plus Xtandi Hit Primary Goal On Thursday, the U.S. drug giant reported topline data from the TALAPRO-3 Phase 3 study of Talzenna (talazoparib)...
Pfizer (PFE) announced positive topline results from the Phase 3 TALAPRO-3 study of talzenna – talazoparib -, an oral poly ADP-ribose polymerase, or PARP, inhib...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, SINGLE-DOSE,...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. The phase 1 study “AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH...
Key Points Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results. Exelixis is a small but su...
Pfizer (NYSE:PFE) reported positive randomized Phase 2 results for atirmociclib, its next generation CDK4 inhibitor, in advanced or metastatic breast cancer. T...
Pfizer Inc. (NYSE:PFE) on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast cancer patients. The trial, whic...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.